title: Dual-modality PET/CT instrumentation-today and tomorrow.
abstract: Positron emission tomography (PET) has proven to be a clinically valuable imaging modality, particularly for oncology staging and therapy follow-up. The introduction of combined PET/CT imaging has helped address challenging imaging situations when anatomical information on PET-only was inadequate for accurate lesion localization. After a decade of PET/CT these combined systems have matured technically. Today, whole-body oncology staging is available with PET/CT in 15 min, or less. This review details recent developments in combined PET/CT instrumentation and points to implications for major applications in clinical oncology.
authors.affiliation: Dept of Clinical Physiology & Nuclear Medicine, Bispebjerg Hospital, Copenhagen University Hospital, DK-2400 Copenhagen NV, Denmark. Markus.Nowak.Lonsdale@bbh.regionh.dk
authors.forename: Markus Nowak
authors.initials: MN
authors.lastname: Lonsdale
authors.forename: Thomas
authors.initials: T
authors.lastname: Beyer
mesh_terms: D016477:Artifacts; D003287:Contrast Media; D004867:Equipment Design; D019788:Fluorodeoxyglucose F18; D006801:Humans; D007089:Image Enhancement / Q000295:instrumentation; D007091:Image Processing, Computer-Assisted / Q000295:instrumentation; D008279:Magnetic Resonance Imaging / Q000295:instrumentation; D008495:Medical Oncology / Q000295:instrumentation*; D009367:Neoplasm Staging / Q000295:instrumentation; D049268:Positron-Emission Tomography / Q000295:instrumentation*; D019275:Radiopharmaceuticals; D015898:Tomography Scanners, X-Ray Computed; D051598:Whole Body Imaging / Q000295:instrumentation*
chemical_list: D003287:Contrast Media; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18